- Dr. Marco Falasca PhD
- Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation; Research Institute, Curtin University, Perth, Western Australia, Australia.
Website | E-mail
Special Issue Introduction
Pancreatic cancer is one of the deadliest forms of cancer with an extremely high mortality rate, mainly because it does not present any symptoms in its early stage and it is usually diagnosed too late. Despite its low incidence, just 9% of all cancers, it remains the 4th leading cause of cancer deaths in the western world, mainly because of its poor diagnosis. Pancreatic cancer is predicted to be the second leading cause of cancer-related mortality by 2030. Therefore, it is imperative to find new therapeutic strategies and valid pharmacological targets to improve the grim survival prospect that oncologists have to offer to pancreatic cancer patients. Although we have witnessed an improvement in the last decade, the survival rate remains very low, below 10%. Available chemotherapies have shown only limited benefits for pancreatic cancer patients, and the failure of the treatments is primarily due to the development of chemoresistance. This Special Issue will discuss the recent development in our understanding of pancreatic cancer chemoresistance and will present novel aspects in the treatment of the disease and explore the state of the art in therapeutics targeting novel molecule under investigation in pancreatic cancer.
KeywordsPancreatic ductal adenocarcinoma, drug resistance, immunotherapy, metastasis, targeted drugs, drug discovery, neoadjuvant therapy
Submission Deadline31 Dec 2020